Abzena started the first half of the year with a strong order book and the positive momentum in trading has continued,shareholders at the annual general meeting today will be told.
An update issued ahead of the meeting says: "The Group is seeing strong growth in revenues from cell line development and bioconjugation projects, with these business areas benefiting most from the synergies derived from the integration of the two US businesses acquired in late 2015.
"Abzena has had a very positive response from its biopharmaceutical customer base to its enlarged service offering. The Group has seen the translation and expansion of a number of relationships with significant further repeat work from major customers. There has also been an increase in demand for development support services for 'Abzena inside' technology licensees.
"Abzena's investment programme to increase capacity at its US sites is ongoing. By the end of the 2016, two new cleanrooms will be available at the San Diego facility and the facility for GMP manufacture of antibody drug conjugate (ADC) linker-payload reagents will be fully operational in Bristol PA (USA)."
Chief executive John Burt said: "Our increased capabilities and capacity are already resulting in an excellent response from customers. The number of projects involving teams from across our research, development and manufacturing offerings, for both 'Abzena inside' partners and service customers is growing healthily. "Our strong current trading is a great endorsement of Abzena's strategy to become a preferred partner for biopharmaceutical services."
At 8:12am: (LON:ABZA) Abzena Plc share price was +1p at 43.5p